Meta description: This report summarizes a regulatory focused clinical trial evaluating the postoperative efficacy of bilateral lumbar erector spinae plane block in lumbar disc herniation repair.
What changed in this trial?
The ClinicalTrials.gov record shows the study is active and not recruiting. The trial is sponsored by Başakşehir Çam & Sakura City Hospital, a Turkish clinical site. The focus is on patients undergoing lumbar disc herniation repair and the role of bilateral lumbar erector spinae plane block in the postoperative period. The primary interests listed reflect analgesia related outcomes rather than definitive efficacy results. The endpoints named in the record include opioid consumption in the postoperative window, the intensity of postoperative pain, the duration of hospital stay, and patient satisfaction with recovery. This entry highlights ongoing evaluation of a regional analgesia technique in spine surgery and signals regulatory interest in accumulating robust safety and performance data before broader adoption. The information in the entry serves to inform regulators, clinicians, and stakeholders about the current stage of evidence collection rather than delivering final conclusions.
What is ESPB and why is it used in spine surgery?
The Bilateral Lumbar Erector Spinae Plane Block is described as a plane block that deposits local anesthetic within the erector spinae region to influence postoperative pain. In the lumbar surgical setting studied here, the technique is presented as part of a pain management strategy intended to reduce opioid requirements and support faster recovery while maintaining safety. The description aligns with a broader movement toward regional anesthesia approaches in spine procedures, where a balance between effective analgesia and minimal systemic exposure is sought. The trial record references this intervention in the context of lumbar disc herniation repair, underscoring its regulatory relevance as a potential analgesic option within standard surgical pathways.
What trial measures are used to assess efficacy?
The registry enumerates endpoints that focus on pain control and recovery. Opioid consumption in the postoperative period is a key metric, alongside patient assessed pain scores. Hospital stay duration and patient satisfaction with the surgical experience are listed as significant endpoints as well. Collectively these measures aim to quantify analgesic performance, patient experience, and resource utilization. The absence of reported results at this stage means readers should interpret the entries as indicators of study design and intent rather than outcomes. This approach supports regulatory aims by clarifying what evidence will be gathered and how it will be analyzed when results become available.
In addition to these outcomes, the record notes the device or technique in question is being evaluated within the framework of a surgical pain management program. The emphasis on a multi dimensional set of endpoints reflects regulatory expectations for comprehensive assessment of safety, effectiveness, and impact on recovery trajectories in spine surgery.
What are the regulatory implications for readers?
The trial status, marked active and not recruiting, indicates that no results are yet ready for regulatory review or broad clinical dissemination. Observers and stakeholders should monitor the ClinicalTrials.gov listing for updates on enrollment, safety events, amendments to protocol, and eventual outcome data. The sponsor being a hospital signals a clinical trial rooted in real world surgical practice, which can influence labeling discussions, consent language, and the recommended use of regional analgesia in spine procedures when evidence matures. For regulatory teams, the entry illustrates how a regional nerve block in a spine procedure is being evaluated under standard trial governance, with explicit attention to postoperative analgesia outcomes and patient experience. Manufacturer statements, if any, would be presented as such and assessed in light of MDR requirements, clinical evidence thresholds, and the evolving body of comparative effectiveness research in postoperative pain management.
What should readers watch next?
The next important step is awaiting updates from the trial registry and official communications from the sponsor site. Readers should check the ClinicalTrials.gov page for NCT07403734 for status changes, enrollment progress, interim findings if any, and final results when they are posted. Hospital announcements and peer reviewed publications may follow, offering detailed safety data and efficacy signals. For regulatory personnel, a key expectation is the potential transition of a regional analgesia approach from an investigational context toward standard practice, which would require formal evaluation of labeling, training requirements, and potential device related risk management updates. The evolving evidence base will determine whether this approach becomes part of regulatory filings or clinical guidelines for spine surgery analgesia.
What are the practical implications for clinical practice?
Practitioners and governance teams should prepare for a period of clinical observation and data collection. If outcomes indicate meaningful reductions in opioid use and satisfactory pain control without added risk, institutions may pilot pathways that incorporate lumbar ESPB into standard care for lumbar disc herniation repair. Conversely, if safety concerns or inconsistent results emerge, the regulatory, educational, and institutional frameworks will guide risk mitigation and alternatives. In all scenarios, the trial’s published protocol and registry data will shape decision making about adoption, training, and patient information materials for regional analgesia approaches in spine surgery.
Frequently asked questions
- 1. What is the Bilateral Lumbar Erector Spinae Plane Block?
A regional anesthesia technique used to manage postoperative pain in the lumbar region by depositing anesthetic in the erector spinae plane.
- 2. What is the focus of the trial?
The trial examines the postoperative analgesic efficacy of this block in patients undergoing lumbar disc herniation repair, with endpoints including opioid use, pain scores, hospital stay, and patient satisfaction.
- 3. Who funds and conducts the trial?
The sponsor is Başakşehir Çam & Sakura City Hospital, a Turkish medical center involved in the study.
- 4. Where can I find official trial information?
The primary registry is ClinicalTrials.gov under identifier NCT07403734.
- 5. When will results be available?
Results will be posted after data analysis and regulatory review, following completion of enrollment and data collection.
Conclusion and implications for readers
This regulatory focused update highlights a live trial evaluating a regional analgesia option in spine surgery. The early signals pertain to study design and planned outcomes rather than measured efficacy. Regulators, clinicians, and device and procedure sponsors should track updates for guidance on safety, performance, and potential implications for labeling and use in lumbar procedures. The registry item serves as a signaling mechanism for forthcoming evidence and helps shape anticipated regulatory expectations for similar techniques in the future.
Disclaimer
This information is intended for professional audiences. It is not legal advice. It does not substitute for regulatory counsel or formal guidance specific to a given jurisdiction or device class.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07403734?term=medical+device